Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer

Feng Shi; Feng-Feng Cai; Lu Cai; Xiao-Yan Lin; Wei Zhang; Qin-Qin Wang; Yu-Jie Zhao; Qi-Chao Ni; Hua Wang; Zhi-Xian He

doi:10.18632/oncotarget.18188

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer

Feng Shi, Feng-Feng Cai, Lu Cai, Xiao-Yan Lin, Wei Zhang, Qin-Qin Wang, Yu-Jie Zhao, Qi-Chao Ni, Hua Wang and Zhi-Xian He _

PDF | HTML | How to cite

Oncotarget. 2017; 8:88453-88463. https://doi.org/10.18632/oncotarget.18188

Metrics: PDF 1275 views | HTML 1890 views | ?

Abstract

Feng Shi1,*, Feng-Feng Cai2,*, Lu Cai2, Xiao-Yan Lin2, Wei Zhang1, Qin-Qin Wang1, Yu-Jie Zhao1, Qi-Chao Ni1, Hua Wang1 and Zhi-Xian He1

1Department of General Surgery, Affiliated Hospital of Nantong University, Nantong University, Nantong, PR China

2Department of Breast Surgery, Yangpu Hospital, Tongji University School of Medicine, Shanghai, PR China

*These authors contributed equally to this work

Correspondence to:

Zhi-Xian He, email: [email protected]

Hua Wang, email: [email protected]

Keywords: SYF2, breast cancer, proliferation, prognosis

Received: January 10, 2017 Accepted: March 30, 2017 Published: May 23, 2017

ABSTRACT

SYF2, a known cell cycle regulator, is reported to be involved in cell cycle arrest by interacting with cyclin-D-type binding protein 1. In the present study, we investigated the role of SYF2 in human breast cancer (BC) progression. SYF2 was highly upregulated in BC tissues and cell lines, as per Western blot and immunohistochemistry analysis. The SYF2 expression level had a significant correlation with the tumor grade and Ki-67 expression. In vitro starvation-refeeding experiment and SYF2-siRNA transfection assay demonstrated that SYF2 could promote proliferation of BC cells, while SYF2 knockdown resulted in cells cycle arrest at G1/S phase, reducing the cell growth rate of BC cells. These results indicated that SYF2 promotes human BC progression by accelerating the BC cells’ proliferation. SYF2 could be a novel therapeutic target in human BC therapies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18188

Publication Alerts

Research Papers:

Overexpression of SYF2 promotes cell proliferation and correlates with poor prognosis in human breast cancer

Abstract